

Product Fact Sheet

HCPCS[†]	Q5128*	Description Injection, ranibizumab-eqrn (CIMERLI), biosimilar, 0.1 mg *For dates of service after 4/1/23
Billable Unit	0.1 mg	<i>For Example</i> 0.5 mg/0.05 mL = 5 billable units 0.3 mg/0.05 mL = 3 billable units
List Price/Wholesale Acquisition Cost (WAC)	0.5 mg/0.05 mL (10 mg/mL) vial (one carton): \$1,360.00 0.3 mg/0.05 mL (6 mg/mL) vial (one carton): \$ 816.00	
NDC¹	0.5 mg/0.05 mL (10 mg/mL) vial (one carton): 70114-0441-01 0.3 mg/0.05 mL (6 mg/mL) vial (one carton): 70114-0440-01	
Product Website	www.CIMERLI.com	
Reference Product	Lucentis [®] (ranibizumab injection)	
How Supplied¹	<ul style="list-style-type: none"> Each CIMERLI[®] 0.5 mg carton contains a single-dose, 2-mL glass vial with a BLUE CAP designed to deliver 0.05 mL of 10 mg/mL ranibizumab-eqrn solution. Each CIMERLI[®] 0.3 mg carton contains a single-dose, 2-mL glass vial with a WHITE CAP designed to deliver 0.05 mL of 6 mg/mL ranibizumab-eqrn solution. EACH CARTON IS FOR SINGLE-EYE USE ONLY	
Storage Information¹	<ul style="list-style-type: none"> CIMERLI[®] should be refrigerated at 2°-8°C (36°-46°F). DO NOT FREEZE. Do not use beyond the expiry date stamped on the label. Protect CIMERLI[®] vials from light and store in the original carton until time of use. 	
Ordering Information	CIMERLI [®] is available through select Specialty Distributors. Contact Coherus BioSciences Customer Services at 1-844-562-6004.	
Return Policy	The return policy may be obtained by contacting Coherus BioSciences Customer Service at 1-844-562-6004.	
Coherus BioSciences Contact Phone Numbers	Medical Information: 1-800-483-3692 Patient Access Support: 1-844-483-3692 Ordering Information: 1-844-562-6004	
Carton Dimensions	3.875" x 1" x 3.25"	
Carton Weight	40.4 grams	
Unit-of-Sale Quantity	1 single-dose glass vial and package insert	
Expiration Date	The expiration date is printed on each CIMERLI [®] vial label and carton.	

Coding is part of the clinical decision. Please use codes that most accurately reflect the procedures performed. Suggestions by Coherus BioSciences do not guarantee reimbursement or take the place of professional coding advice.



Please see attached full Prescribing Information.

[†]CMS.gov; <https://www.cms.gov/files/document/2022-hcpcs-application-summary-quarter-4-2022-drugs-and-biologicals-updated-02/01/2023.pdf>, Accessed February 2, 2023

1. CIMERLI[®] (ranibizumab-eqrn) [prescribing information]. Redwood City, CA: Coherus BioSciences, Inc.; 2022

CIMERLI is a registered trademark of Coherus BioSciences, Inc.

Lucentis is a registered trademark of Genentech, Inc.

© 2023 Coherus BioSciences, Inc. All rights reserved. 0223-CIM-P015r2